Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18764540 | MODULATORS OF LIVER RECEPTOR HOMOLOGUE 1 (LRH-1) AND USES | July 2024 | May 2025 | Allow | 11 | 0 | 1 | Yes | No |
| 18659715 | Compositions and Methods For Reducing Immune Intolerance and Treating Autoimmune Disorders | May 2024 | April 2025 | Allow | 11 | 0 | 1 | Yes | No |
| 18625130 | 2-(BENZO[D]OXAZOL-2-YL)-N'-(3,5-DICHLOROBENZOYLOXY)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | April 2024 | July 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18603405 | NOVEL 3, 5-DISUBSTITUTED PYRIDINE AND 3, 5-DISUBSTITUTED PYRIDAZINE DERIVATIVES AND PHARMACEUTICAL USE OF SAME | March 2024 | April 2025 | Allow | 13 | 1 | 0 | No | No |
| 18440576 | POLYMERASE INHIBITORS AND RELATED COMPOSITIONS AND METHODS | February 2024 | December 2024 | Allow | 11 | 0 | 0 | No | No |
| 18440563 | SPRAY-DRIED DISPERSIONS, FORMULATIONS, AND POLYMORPHS OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)-1-(1,1,1-TRIFLUOROPROPAN-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE | February 2024 | December 2024 | Allow | 10 | 1 | 0 | No | No |
| 18428327 | METHYL 4-((5-(3-FLUOROPHENYL)-4-PHENYL-4H-1,2,4-TRIAZOL-3-YLTHIO)METHYL)BENZOATE AS AN ANTIMICROBIAL COMPOUND | January 2024 | May 2024 | Allow | 4 | 0 | 0 | No | No |
| 18428286 | METHYL 4-((5-(3-FLUOROPHENYL)-4-PHENYL-4H-1,2,4-TRIAZOL-3-YLTHIO)METHYL)BENZOATE AS AN ANTIMICROBIAL COMPOUND | January 2024 | June 2024 | Allow | 4 | 0 | 0 | No | No |
| 18421117 | SIRTUIN MODULATING COMPOUNDS AND APPLICATIONS THEREOF | January 2024 | September 2024 | Allow | 8 | 0 | 0 | Yes | No |
| 18416748 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | January 2024 | September 2024 | Allow | 8 | 0 | 0 | No | No |
| 18416734 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | January 2024 | October 2024 | Allow | 9 | 0 | 0 | Yes | No |
| 18414924 | N'-(2-NAPHTHOYLOXY)-2-(BENZO[D]OXAZOL-2-YL)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | January 2024 | August 2024 | Allow | 7 | 1 | 0 | No | No |
| 18414737 | N'-(2-NAPHTHOYLOXY)-2-(BENZO[D]OXAZOL-2-YL)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | January 2024 | September 2024 | Allow | 8 | 1 | 0 | No | No |
| 18394977 | 3,5-DINITRO-N-(PYRIMIDIN-2-YLCARBAMOTHIOYL)BENZAMIDE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.) | December 2023 | March 2024 | Allow | 3 | 0 | 0 | No | No |
| 18394534 | 3,5-DINITRO-N-(PYRIMIDIN-2-YLCARBAMOTHIOYL)BENZAMIDE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.) | December 2023 | May 2024 | Allow | 4 | 0 | 0 | No | No |
| 18394610 | (E)-2-(3-CYANO-4-ISOBUTOXYPHENYL)-N'-(SUBSTITUTED BENZYLIDENE)-4-METHYLTHIAZOLE-5-CARBOHYDRAZIDES AS ANTI-TUBERCULAR AGENTS | December 2023 | July 2024 | Allow | 7 | 0 | 0 | Yes | No |
| 18543793 | CRYSTALLINE FORMS OF (S)-1-(4-FLUOROPHENYL)-1-(2-(4-(6-(1- METHYL-1H-PYRAZOL-4-YL)PYRROLO[2,1-F][1,2,4]TRIAZIN-4-YL)PIPERAZINYL)-PYRIMIDIN-5-YL)ETHAN-1-AMINE AND METHODS OF MAKING | December 2023 | March 2024 | Allow | 3 | 0 | 0 | Yes | No |
| 18530774 | ANTI-FUNGALS COMPOUNDS TARGETING THE SYNTHESIS OF FUNGAL SPHINGOLIPIDS | December 2023 | January 2025 | Allow | 14 | 1 | 0 | No | No |
| 18530782 | STRESS TEST AND TREATMENT OF CHRONIC KIDNEY DISEASE | December 2023 | August 2024 | Allow | 8 | 0 | 0 | Yes | No |
| 18520037 | HETEROCYCLIC COMPOUND AND USE THEREOF | November 2023 | June 2025 | Abandon | 19 | 0 | 0 | No | No |
| 18510888 | BORON CONTAINING PYRAZOLE COMPOUNDS, COMPOSITIONS COMPRISING THEM, METHODS AND USES THEREOF | November 2023 | April 2025 | Allow | 17 | 1 | 1 | No | No |
| 18445603 | Dosage Unit Form(s) Comprising BTS and BTS(OMe) For Use In Boron Neutron Capture Therapy and Methods Thereof | November 2023 | July 2024 | Allow | 8 | 0 | 0 | Yes | No |
| 18504164 | BORON-CONTAINING COMPOUND AND ELECTROLYTE ADDITIVE FOR SECONDARY BATTERY CONTAINING THE SAME | November 2023 | September 2024 | Allow | 10 | 1 | 0 | No | No |
| 18502094 | BORON-CONTAINING COMPOUND AND ELECTROLYTE SOLUTION ADDITIVE FOR SECONDARY BATTERY INCLUDING THE SAME | November 2023 | September 2024 | Allow | 10 | 1 | 0 | No | No |
| 18495755 | BORON-CONTAINING COMPOUND AND ELECTROLYTE SOLUTION ADDITIVE FOR SECONDARY BATTERY INCLUDING THE SAME | October 2023 | February 2025 | Allow | 16 | 1 | 0 | No | No |
| 18384254 | 3,5-DINITRO-N-(PYRIMIDIN-2-YLCARBAMOTHIOYL)BENZAMIDE AS AN ECO-FRIENDLY INSECTICIDAL AGENT AGAINST SPODOPTERA LITTORALIS (BOISD.) | October 2023 | March 2024 | Allow | 5 | 1 | 1 | No | No |
| 18382832 | 2-(BENZO[D]OXAZOL-2-YL)-N'-(3,5-DICHLOROBENZOYLOXY)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | October 2023 | March 2024 | Allow | 5 | 0 | 1 | Yes | No |
| 18382959 | METHYL 4-((5-(3-FLUOROPHENYL)-4-PHENYL-4H-1,2,4-TRIAZOL-3-YLTHIO)METHYL)BENZOATE AS AN ANTIMICROBIAL COMPOUND | October 2023 | August 2024 | Abandon | 10 | 1 | 1 | No | No |
| 18380962 | Immunoproteasome Inhibitors | October 2023 | January 2025 | Allow | 15 | 1 | 1 | No | No |
| 18379999 | N'-(2-NAPHTHOYLOXY)-2-(BENZO[D]OXAZOL-2-YL)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | October 2023 | March 2024 | Allow | 5 | 1 | 1 | Yes | No |
| 18483128 | A2-73 AS A THERAPEUTIC FOR INSOMNIA, ANXIETY AND AGITATION | October 2023 | December 2024 | Allow | 15 | 1 | 0 | No | No |
| 18377533 | (E)-2-(3-CYANO-4-ISOBUTOXYPHENYL)-N'-(SUBSTITUTED BENZYLIDENE)-4-METHYLTHIAZOLE-5-CARBOHYDRAZIDES AS ANTI-TUBERCULAR AGENTS | October 2023 | August 2024 | Allow | 10 | 2 | 1 | No | No |
| 18372935 | 1-CYCLOPROPYL-6-FLUORO-4-OXO-7-(4-((2-THIOXOBENZO[D]THIAZOL-3(2H)-YL)METHYL)PIPERAZIN-1-YL)-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID AS AN ANTIMICROBIAL COMPOUND | September 2023 | December 2023 | Allow | 2 | 0 | 0 | Yes | No |
| 18372980 | PROCESSES FOR THE PREPARATION OF ORTHO-ALLYLATED HYDROXY ARYL COMPOUNDS | September 2023 | December 2024 | Abandon | 15 | 0 | 1 | No | No |
| 18472105 | THERAPEUTIC COMPOUNDS AND METHODS OF USE | September 2023 | May 2025 | Allow | 20 | 1 | 1 | No | No |
| 18470029 | BICYCLIC CX3CR1 RECEPTOR AGONISTS | September 2023 | November 2024 | Allow | 14 | 0 | 1 | No | No |
| 18469323 | ACYLOXY SUBSTITUTED PHENYL DITHIANE DERIVATIVES | September 2023 | October 2024 | Allow | 13 | 1 | 1 | No | No |
| 18239892 | TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA | August 2023 | July 2024 | Allow | 11 | 0 | 1 | No | No |
| 18449741 | OPIOID FOR USE TO REDUCE AND/OR DRUG ADDICTION | August 2023 | October 2024 | Allow | 14 | 0 | 0 | No | No |
| 18361430 | AMINOTHIAZOLE COMPOUNDS AS C-KIT INHIBITORS | July 2023 | October 2024 | Allow | 15 | 0 | 0 | Yes | No |
| 18355945 | MANUFACTURE OF TRANS-[TETRACHLOROBIS(1H-INDAZOLE)RUTHENATE (III)] AND COMPOSITIONS THEREOF | July 2023 | April 2025 | Allow | 21 | 1 | 1 | Yes | No |
| 18355178 | METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA | July 2023 | October 2024 | Abandon | 15 | 0 | 1 | No | No |
| 18220739 | Antioxidant Vitamin C Derivative | July 2023 | December 2023 | Allow | 5 | 1 | 0 | No | No |
| 18218128 | METHOD FOR PREPARING 2,5-FURANDICARBOXYLIC ACID (FDCA) FROM FURFURAL | July 2023 | October 2023 | Allow | 4 | 0 | 0 | No | No |
| 18213557 | TARGETING OF ENDOPLASMIC RETICULUM DYSFUNCTION AND PROTEIN FOLDING STRESS TO TREAT NEUROLOGICAL CONDITIONS | June 2023 | July 2024 | Allow | 13 | 1 | 0 | No | No |
| 18210763 | GLUCOSE-SENSITIVE ALBUMIN-BINDING DERIVATIVES | June 2023 | November 2024 | Allow | 17 | 1 | 1 | Yes | No |
| 18334355 | DIARYLHYDANTOIN COMPOUNDS | June 2023 | October 2024 | Allow | 17 | 0 | 0 | No | No |
| 18206005 | SUBSTITUTED PHENYL SULFONYL PHENYL TRIAZOLE THIONES AND USES THEREOF | June 2023 | November 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18328658 | BENZOTHIA(DI)AZEPINE COMPOUNDS AND THEIR USE AS BILE ACID MODULATORS | June 2023 | September 2024 | Allow | 15 | 1 | 1 | No | No |
| 18328242 | MONOACYLGLYCEROL LIPASE MODULATORS | June 2023 | December 2024 | Abandon | 18 | 1 | 0 | No | No |
| 18204649 | PHARMACEUTICAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF TREATING ASTHMA AND OTHER DISORDERS | June 2023 | June 2024 | Allow | 12 | 1 | 1 | No | No |
| 18200431 | Modulators of Liver Receptor Homologue 1 (LRH-1) and Uses | May 2023 | April 2024 | Allow | 11 | 0 | 1 | Yes | No |
| 18314560 | THERAPEUTIC USES OF PHARMACEUTICAL COMPOSITIONS COMPRISING CYCLIC BORONIC ACID ESTER DERIVATIVES | May 2023 | August 2024 | Allow | 15 | 0 | 1 | No | No |
| 18183655 | TREATMENT OF CIRCADIAN RHYTHM DISORDERS | March 2023 | October 2023 | Allow | 7 | 0 | 1 | Yes | No |
| 18120110 | TREPROSTINIL PRODRUGS | March 2023 | August 2024 | Allow | 17 | 0 | 0 | No | No |
| 18172024 | Polyethylene Glycol-Conjugated Glucocorticoid Prodrugs and Compositions and Methods Thereof | February 2023 | February 2024 | Allow | 11 | 0 | 1 | No | No |
| 18169702 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X2 AND RELATED PRODUCTS AND METHODS | February 2023 | July 2024 | Allow | 17 | 1 | 1 | No | No |
| 18110260 | PHARMACEUTICAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF TREATING ASTHMA AND OTHER DISORDERS | February 2023 | July 2023 | Allow | 5 | 0 | 0 | Yes | No |
| 18109705 | INHIBITORS OF ECTONUCLEOTIDE PYROPHOSPHATASE/PHOSPHODIESTERASE 1 (ENPP1) AND METHODS OF USE THEREOF | February 2023 | June 2024 | Allow | 16 | 1 | 1 | Yes | No |
| 18168128 | Compositions and Methods For Reducing Immune Intolerance and Treating Autoimmune Disorders | February 2023 | February 2024 | Allow | 12 | 1 | 1 | No | No |
| 18159447 | ALKYLAMINE-SUBSTITUTED PERTHIOCARBAMATES AS DUAL PRECURSORS TO HYDROPERSULFIDE AND CARBONYL SULFIDE | January 2023 | December 2023 | Abandon | 11 | 0 | 1 | No | No |
| 18158046 | cGAS ANTAGONIST COMPOUNDS | January 2023 | March 2024 | Allow | 14 | 1 | 1 | No | No |
| 18100330 | SYNTHESIS OF ESUBERAPROST PRODRUGS | January 2023 | July 2024 | Allow | 18 | 0 | 0 | No | No |
| 18099060 | REAGENTS AND PROCESS FOR DIRECT C-H FUNCTIONALIZATION | January 2023 | March 2024 | Allow | 14 | 1 | 1 | Yes | No |
| 18099082 | COMPOUNDS, COMPOSITIONS, AND METHODS | January 2023 | July 2023 | Allow | 6 | 0 | 0 | No | No |
| 18155340 | SYNTHESIS OF SUBSTITUTED FURANS | January 2023 | July 2024 | Allow | 18 | 0 | 0 | No | No |
| 18093910 | SEPARATION OF CHEMICAL SPECIES USING MULTIPLE LIQUID PHASES AND RELATED SYSTEMS | January 2023 | August 2024 | Allow | 20 | 0 | 0 | No | No |
| 18090953 | SIRTUIN MODULATING COMPOUNDS AND APPLICATIONS THEREOF | December 2022 | February 2024 | Allow | 14 | 1 | 1 | Yes | No |
| 18145909 | 2-Pyrazole Anilines and Related Analogs for Inhibiting YAP/TAZ-TEAD | December 2022 | October 2023 | Allow | 10 | 0 | 1 | Yes | No |
| 18087233 | HETEROCYCLIC NMDA ANTAGONISTS | December 2022 | April 2023 | Allow | 4 | 0 | 0 | No | No |
| 18012540 | HALOALLYLAMINE DUAL AMINE OXIDASE INHIBITORS | December 2022 | June 2025 | Allow | 30 | 0 | 0 | No | No |
| 18012586 | METHOD FOR PREPARING 2-IODOHETEROCYCLIC ARYL ETHER AT ROOM TEMPERATURE | December 2022 | June 2025 | Allow | 30 | 1 | 1 | Yes | No |
| 18086122 | BORON-CONTAINING COMPOUND AND ELECTROLYTE SOLUTION ADDITIVE FOR SECONDARY BATTERY INCLUDING THE SAME | December 2022 | September 2023 | Allow | 9 | 0 | 1 | No | No |
| 18083037 | C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | December 2022 | February 2024 | Abandon | 14 | 1 | 1 | No | No |
| 18066954 | LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS | December 2022 | May 2024 | Allow | 17 | 1 | 1 | No | No |
| 18078671 | BORON-CONTAINING COMPOUND AND ELECTROLYTE SOLUTION ADDITIVE FOR SECONDARY BATTERY INCLUDING THE SAME | December 2022 | October 2023 | Allow | 10 | 0 | 1 | No | No |
| 18075610 | BORON-CONTAINING COMPOUND AND ELECTROLYTE ADDITIVE FOR SECONDARY BATTERY CONTAINING THE SAME | December 2022 | September 2023 | Allow | 9 | 0 | 1 | No | No |
| 18059332 | REELIN/VEGF-C PRODUCTION/ACTIVATION PROMOTER AND SKIN EXTERNAL COMPOSITION USING THE SAME | November 2022 | January 2024 | Allow | 14 | 1 | 1 | Yes | No |
| 17999195 | MALONITRILE DERIVATIVES | November 2022 | June 2025 | Allow | 31 | 0 | 0 | No | No |
| 18055873 | FLAVAN-3-OL ANALOGS AND ANTI-INFLAMMATORY ACTIVITY | November 2022 | January 2024 | Allow | 14 | 1 | 1 | Yes | No |
| 18054558 | NOVEL LAUROLACTAM PREPARATION METHOD AND SYNTHESIS APPARATUS | November 2022 | July 2024 | Allow | 20 | 0 | 0 | No | No |
| 17984242 | 4-IMIDAZOPYRIDAZIN-1-YL-BENZAMIDES AS BTK INHIBITORS | November 2022 | February 2025 | Abandon | 28 | 1 | 0 | No | No |
| 17998344 | PROCESSES FOR THE PYROLYSIS OF CARBOHYDRATES | November 2022 | May 2025 | Allow | 31 | 0 | 0 | No | No |
| 17974569 | ANTIMALARIAL COMPOSITIONS AND USES THEREOF | October 2022 | January 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18049517 | POLYMERASE INHIBITORS AND RELATED COMPOSITIONS AND METHODS | October 2022 | November 2023 | Allow | 12 | 1 | 0 | Yes | No |
| 17971959 | METHOD FOR SYNTHESIZING (RS)-WARFARIN | October 2022 | August 2023 | Allow | 9 | 0 | 0 | No | No |
| 17964347 | PROCESSES FOR THE PREPARATION OF ORTHO-ALLYLATED HYDROXY ARYL COMPOUNDS | October 2022 | June 2023 | Allow | 8 | 0 | 0 | No | No |
| 17936947 | METHODS AND COMPOSITIONS FOR ASSESSING CELL VIABILITY | September 2022 | May 2023 | Allow | 7 | 0 | 0 | Yes | No |
| 17936576 | N-(SUBSTITUTED-PHENYL)-SULFONAMIDE DERIVATIVES AS KINASE INHIBITORS | September 2022 | July 2023 | Allow | 10 | 1 | 0 | No | No |
| 17912404 | 3-DIARYLMETHYLENES AND USES THEREOF | September 2022 | April 2025 | Allow | 31 | 0 | 1 | No | No |
| 17944782 | DIAMINE DERIVATIVES AS INHIBITORS OF LEUKOTRIENE A4 HYDROLASE | September 2022 | August 2024 | Allow | 23 | 1 | 1 | No | No |
| 17888142 | Indole Compounds and Their Use | August 2022 | September 2023 | Allow | 13 | 1 | 0 | No | No |
| 17886926 | Compositions and Methods For Reducing Immune Intolerance and Treating Autoimmune Disorders | August 2022 | January 2023 | Allow | 5 | 0 | 1 | Yes | No |
| 17803487 | Borylated Amino Acid Compositions Comprising BTS and BTS(OMe) For Use in Boron Neutron Capture Treapy and Methods Thereof | August 2022 | October 2023 | Allow | 11 | 0 | 1 | Yes | No |
| 17874700 | NOVEL CRYSTALLINE FORM OF 1-(5-(2,4-DIFLUOROPHENYL)-1-((3-FLUOROPHENYL)SULFONYL)-4-METHOXY-1H-PYRROL-3-YL)-N-METHYLMETHANAMINE SALT | July 2022 | May 2023 | Allow | 10 | 0 | 0 | Yes | No |
| 17792298 | METHODS, PROCESSES AND INTERMEDIATES FOR PREPARING CHROMAN COMPOUNDS | July 2022 | April 2025 | Allow | 33 | 0 | 1 | Yes | No |
| 17862896 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | July 2022 | December 2023 | Abandon | 17 | 1 | 0 | No | No |
| 17790442 | METHOD FOR PREPARING ACRYLONITRILE DIMER | June 2022 | August 2023 | Allow | 13 | 0 | 0 | No | No |
| 17788716 | PREPARATION OF CANNABICHROMENE AND RELATED CANNABINOIDS | June 2022 | January 2025 | Allow | 31 | 0 | 0 | No | No |
| 17786871 | METHODS OF PRODUCING DIMETHYL CARBONATE | June 2022 | April 2024 | Allow | 22 | 1 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SHAMEEM, GOLAM M.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 100.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner SHAMEEM, GOLAM M works in Art Unit 1621 and has examined 934 patent applications in our dataset. With an allowance rate of 95.2%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 24 months.
Examiner SHAMEEM, GOLAM M's allowance rate of 95.2% places them in the 86% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by SHAMEEM, GOLAM M receive 0.69 office actions before reaching final disposition. This places the examiner in the 6% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by SHAMEEM, GOLAM M is 24 months. This places the examiner in the 70% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +6.7% benefit to allowance rate for applications examined by SHAMEEM, GOLAM M. This interview benefit is in the 35% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 45.6% of applications are subsequently allowed. This success rate is in the 96% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 85.4% of cases where such amendments are filed. This entry rate is in the 97% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 84% percentile among all examiners. Of these withdrawals, 60.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 31.9% are granted (fully or in part). This grant rate is in the 25% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 27.4% of allowed cases (in the 100% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 9.4% of allowed cases (in the 87% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.